Philips released its Future Health Index 2026 report this month, documenting measurable productivity gains for clinicians using AI-assisted tools — a finding that carries downstream implications for the functional foods and nutraceutical supply chain. While the report focuses on hospital and primary-care workflows, operators in finished formulation, contract manufacturing, and regulatory affairs are increasingly fielding the same technology stack the report describes.
The core signal from the Philips data is that AI is compressing time-to-decision in evidence-heavy environments. For nutraceutical brands, that dynamic maps directly onto the bottlenecks most familiar to product developers: literature review for structure-function claims, bioavailability modeling across delivery formats, and the documentation burden associated with GRAS self-affirmation or New Dietary Ingredient (NDI) notifications filed with FDA. Early adopters in the ingredient supply chain have begun piloting large-language-model tools to accelerate dossier preparation and flag gaps in clinical endpoint coverage before submissions are filed.
The broader market context matters here. The global functional food and beverage category is tracking toward significant expansion through the late 2020s, with condition-specific segments — cardiovascular, cognitive, metabolic — demanding increasingly rigorous substantiation to support structure-function claims at retail. Consumers in these segments skew toward health-literate buyers who cross-reference peer-reviewed literature, raising the bar for brands that want to compete on evidence rather than heritage positioning. Co-manufacturing partners and white-label suppliers are responding by investing in scientific affairs capabilities that would have been cost-prohibitive without AI-assisted research tools.
For operators, the practical opportunity lies at the intersection of AI-accelerated evidence synthesis and the compliance infrastructure already required by finished formulation businesses. Brands building out clinical substantiation programs can use the same AI tooling Philips documents in clinical settings to map existing randomized, double-blind, placebo-controlled trial data against their ingredient portfolios — identifying where standardized extract concentrations and mg/serving doses align with published clinical endpoints, and where gaps remain. The same logic applies to regulatory strategy, where AI tools are shortening the timeline between ingredient sourcing and label-ready claim approval.
The Philips report stops short of addressing nutraceutical applications directly, but its central finding — that AI delivers measurable impact in evidence-intensive professional environments — is a prompt the functional foods industry should not need twice. Brands and their manufacturing partners that build AI-literacy into their scientific and regulatory workflows now are likely to hold a formulation and speed-to-market advantage as substantiation requirements tighten. Coverage of this report is supported by the Food & Beverage Magazine network.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.